Form 4: Immuneering Corp Director Ann E. Berman Acquires Stock Options

Director Ann E. Berman acquired stock options in Immuneering Corp as part of the company's Non-Employee Director Compensation Program.

Summary

• Ann E. Berman, a director at Immuneering Corp, acquired two stock option grants on January 1, 2025.
• The first grant is for 23,485 shares, received in lieu of a cash Base Retainer.
• The second grant is for 17,614 shares, received in lieu of a cash COB Retainer.
• Both options have an exercise price of $2.20 per share and expire on January 1, 2035.
• The options vest in four equal installments, with the first vesting after three months of continuous service and the final vesting on the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns interests. There are no indications of any negative issues.

Positives

• The stock options were granted as part of the company's Non-Employee Director Compensation Program, aligning director interests with company performance.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the stock options is dependent on the future performance of Immuneering Corp's stock price.
• The options will only vest if the director continues to serve on the board.

Industry Context

This is a standard practice for compensating non-employee directors in publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for non-employee directors in the biotechnology industry.
• The vesting schedule of one year is typical for these types of grants.
• The exercise price is set at a fixed value, which is standard practice.

Stakeholder Impact

• The stock option grants align the director's interests with those of shareholders, potentially leading to better corporate governance and decision-making.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, director compensation, insider trading, equity, IMRX, Immuneering Corp